Sonnet BioTherapeutics Holdings, Inc.
SONN
$4.97
-$0.88-15.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.00M | 0.00 | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.00M | 0.00 | -- |
| Cost of Revenue | 2.43M | 1.88M | 1.89M | -4.43M | 1.73M |
| Gross Profit | -2.43M | -1.88M | -886.10K | 4.43M | -1.73M |
| SG&A Expenses | 1.38M | 2.34M | 1.96M | 1.97M | 1.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.81M | 4.23M | 3.85M | 3.17M | 3.53M |
| Operating Income | -3.81M | -4.23M | -2.85M | -3.17M | -3.53M |
| Income Before Tax | -3.78M | -3.49M | -3.00M | -3.13M | -3.51M |
| Income Tax Expenses | -- | -- | 158.40K | -- | -- |
| Earnings from Continuing Operations | -3.78M | -3.49M | -3.16M | -3.13M | -3.51M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.78M | -3.49M | -3.16M | -3.13M | -3.51M |
| EBIT | -3.81M | -4.23M | -2.85M | -3.17M | -3.53M |
| EBITDA | -3.80M | -4.23M | -2.85M | -3.17M | -3.53M |
| EPS Basic | -0.95 | -0.89 | -1.56 | -3.33 | -5.57 |
| Normalized Basic EPS | -0.60 | -0.56 | -0.93 | -2.08 | -3.48 |
| EPS Diluted | -0.95 | -0.89 | -1.56 | -3.33 | -5.57 |
| Normalized Diluted EPS | -0.60 | -0.56 | -0.93 | -2.08 | -3.48 |
| Average Basic Shares Outstanding | 3.97M | 3.92M | 2.02M | 940.30K | 629.70K |
| Average Diluted Shares Outstanding | 3.97M | 3.92M | 2.02M | 940.30K | 629.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |